Core Insights - The company reported a total operating revenue of 327 million yuan for the fiscal year 2025, representing a year-on-year growth of 19.96% [1] - The net profit reached 84.09 million yuan, showing a significant increase of 62.04% compared to the previous year [1] Revenue and Profit Growth - The revenue growth is attributed to the company's innovation-driven strategy and a dual domestic and international market approach [1] - The sales revenue from endoscopic staplers continued to grow steadily during the reporting period [1] Cost Optimization and Profitability - The company experienced an increase in gross profit margin year-on-year, which contributed to the overall profit increase [1] - The scale effect of products and cost optimization strategies played a crucial role in enhancing profitability [1]

天臣医疗公告称，预计2025年年度归属于母公司所有者的净利润增加3100.00万元到3700.00万元，同比 增加59.74%到71.30%；扣非净利润增加2700.00万元到3100.00万元，同比增加57.77%到66.32%。上年同 期净利润为5189.48万元，扣非净利润为4674.08万元。业绩增长主要因报告期内腔镜吻合器类产品销售 收入稳定增长，以及汇率波动使汇兑收益同比增加。预告未经审计，具体数据以年报为准。 ...